Evidence map›Paper›PMID 41526801›Full record

ReviewFolia microbiologica2026

Glutathione redox system as a therapeutic target for Plasmodium: Opportunities, Challenges, and future perspectives.

Richa Prasad Mahato, Soniya Kumbham, Saurabh Kumar, Sanjay Ch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Revisiting Glutathione Transferases ofPharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Richa Prasad MahatoDepartment of Biological Sciences, CHARUSAT campus, P. D. Patel Institute of Applied Sciences, Charotar University of Science and Technology, Changa, Gujarat, 388 412, India. prasadricha333@gmail.com.ORCID http://orcid.org/0000-0003-1560-8206
Soniya KumbhamDepartment of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, 14214, USA.
Saurabh KumarVersiti Blood Research Institute, Milwaukee, WI, 53226, USA. saurabhmicro999@gmail.com.ORCID http://orcid.org/0000-0002-2143-6415
Sanjay ChDepartment of Ophthalmology and Visual Sciences, Froedtert Eye Institute, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutathione (GSH) serves as an essential guardian for parasites, protecting them from the onslaught of oxidative stress. As hemoglobin breaks down and energy is harvested through the intricate mitochondrial respiratory pathway, GSH meticulously creates a reducing environment, akin to a fortress against oxidative damage. The metabolic pathways involving GSH in parasites are complex and markedly different from those in human hosts, rendering them a compelling target in the battle against multidrug-resistant parasites. This review illuminates the critical role of GSH in the survival of malaria parasites and the impact of key enzyme inhibitors on the GSH redox pathway. Recent discoveries surrounding significant enzyme inhibitors as GST, GR, GS, and GP, are explored, shedding light on the potential of combination therapies while underscoring the obstacles posed by selective drug targeting and the imperative to navigate drug resistance. Moreover, the review delves into the forefront of research on the metabolic pathways of GSH in parasites, unveiling a trove of promising drug targets for strategies aimed at treating malaria in an era plagued by multidrug resistance and offers hope for innovative therapeutic approaches against one of the world's most persistent diseases.

Indexed as

AntimalarialsGlutathioneMalariaPlasmodiumAnimalsEnzyme InhibitorsHumansMetabolic Networks and PathwaysOxidation-ReductionOxidative StressAntimalarialsEnzyme InhibitorsGlutathioneAntimalarial therapyDrug resistanceGlutathione metabolismPlasmodiumTherapeutic targets

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.